Sanjeev Krishna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7212548/publications.pdf

Version: 2024-02-01

211 papers	15,294 citations	23500 58 h-index	20900 115 g-index
217 all docs	217 docs citations	217 times ranked	13075 citing authors

#	Article	IF	Citations
1	Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Advances, 2022, 6, 652-663.	2.5	4
2	Fluid therapy for severe malaria. Lancet Infectious Diseases, The, 2022, 22, e160-e170.	4.6	5
3	Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast. Antimicrobial Agents and Chemotherapy, 2022, , e0207921.	1.4	2
4	How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review. Malaria Journal, 2022, 21, .	0.8	4
5	Need for optimized dosages in the design of comparative clinical trials of anti-malarial drugs. Malaria Journal, 2022, 21, .	0.8	0
6	Repurposing Antimalarials to Tackle the COVID-19 Pandemic. Trends in Parasitology, 2021, 37, 8-11.	1.5	45
7	Insights from compassionate use of tocilizumab for COVIDâ€19 to inform appropriate design of randomised controlled trials. British Journal of Clinical Pharmacology, 2021, 87, 1584-1586.	1.1	6
8	IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Emerging Infectious Diseases, 2021, 27, 85-91.	2.0	35
9	Longitudinal Monitoring of Lactate in Hospitalized and Ambulatory COVID-19 Patients. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	15
10	Development and Validation of an In Silico Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
11	Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment. Antimicrobial Agents and Chemotherapy, 2021, 65, e0027521.	1.4	6
12	Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009551.	1.3	25
13	The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational study. Lancet Haematology,the, 2020, 7, e789-e797.	2.2	13
14	Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing. , 2020, 216, 107706.		48
15	Suboptimal dosing triggers artemisinin partner drug resistance. Lancet Infectious Diseases, The, 2019, 19, 1167-1168.	4.6	11
16	Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case against. Malaria Journal, 2019, 18, 339.	0.8	18
17	A Temporizing Solution to â€œArtemisinin Resistanceâ€• New England Journal of Medicine, 2019, 380, 2087-2089.	13.9	69
18	Detectable Vesicular Stomatitis Virus (VSV)â€“Specific Humoral and Cellular Immune Responses Following VSVâ€“Ebola Virus Vaccination in Humans. Journal of Infectious Diseases, 2019, 219, 556-561.	1.9	29

#	Article	IF	Citations
19	Widening the options for recurrent malaria. Lancet, The, 2018, 391, 1336-1338.	6.3	0
20	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infectious Diseases, The, 2018, 18, 738-748.	4.6	62
21	Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2018, 73, 581-595.	1.3	37
22	The current landscape of nucleic acid tests for filovirus detection. Journal of Clinical Virology, 2018, 103, 27-36.	1.6	13
23	Molecular assays for antimalarial drug resistance surveillance: A target product profile. PLoS ONE, 2018, 13, e0204347.	1.1	24
24	Evidence for Regulation of Hemoglobin Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine Resistance Transporter. Scientific Reports, 2018, 8, 13578.	1.6	24
25	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine, 2017, 19, 107-118.	2.7	64
26	Answer to the comment of Hai Lu et al. regarding â€œHepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)â€¦ Archives of Toxicology, 2017, 91, 2491-2492.	1.9	2
27	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, 2017, 20, 2251-2261.	2.9	107
28	Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity. ACS Central Science, 2017, 3, 743-750.	5.3	86
29	Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria. Malaria Journal, 2017, 16, 217.	0.8	20
30	Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature. Archives of Toxicology, 2017, 91, 1833-1846.	1.9	45
31	SAFETY OF RVSV EBOLA VACCINE, AFTER 6 MONTHS FOLLOW-UP, IN ADULTS: A PHASE 1 TRIAL CONDUCTED IN LAMBARÃ‰NÃ‰, GABON. BMJ Global Health, 2017, 2, A67.1-A67.	2.0	0
32	Safety and immunogenicity of rVSVÎ”G-ZEBOV-GP Ebola vaccine in adults and children in LambarÃ©nÃ©, Gabon: A phase I randomised trial. PLoS Medicine, 2017, 14, e1002402.	3.9	57
33	Transmembrane solute transport in the apicomplexan parasite Plasmodium. Emerging Topics in Life Sciences, 2017, 1, 553-561.	1.1	4
34	Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1001938.	3.9	44
35	Methylene Homologues of Artemisone: An Unexpected Structureâ€“Activity Relationship and a Possible Implication for the Design of C10â€Substituted Artemisinins. ChemMedChem, 2016, 11, 1469-1479.	1.6	20
36	Non-randomised Ebola trialsâ€”lessons for optimal outbreak research. Lancet Infectious Diseases, The, 2016, 16, 407-408.	4.6	5

#	Article	IF	Citations
37	Artemisinin Resistance and the Blame Game. Clinical Infectious Diseases, 2016, 63, 1144-1145.	2.9	5
38	A vacuolar iron-transporter homologue acts as a detoxifier in Plasmodium. Nature Communications, 2016, 7, 10403.	5.8	45
39	Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacological Research, 2016, 110, 216-226.	3.1	82
40	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New England Journal of Medicine, 2016, 374, 1647-1660.	13.9	355
41	Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasiteâ€™s food vacuole and alter drug sensitivities. Scientific Reports, 2015, 5, 14552.	1.6	59
42	Plasmodium knowlesi Genome Sequences from Clinical Isolates Reveal Extensive Genomic Dimorphism. PLoS ONE, 2015, 10, e0121303.	1.1	54
43	The wisdom of crowds and the repurposing of artesunate as an anticancer drug. Ecancermedicalscience, 2015, 9, ed50.	0.6	25
44	Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?. Lancet Infectious Diseases, The, 2015, 15, 738-745.	4.6	42
45	A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine, 2015, 2, 82-90.	2.7	155
46	Ebola: missed opportunities for Europeâ€“Africa research. Lancet Infectious Diseases, The, 2015, 15, 1254-1255.	4.6	13
47	Delayed haemolysis after artesunate treatment of severe malaria â€“ Review of the literature and perspective. Travel Medicine and Infectious Disease, 2015, 13, 143-149.	1.5	36
48	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	2.3	37
49	Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions - a prospective multicenter cohort study. BMC Medicine, 2015, 13, 125.	2.3	16
50	Delayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malariaâ€”A Double-center Prospective Study. Journal of Infectious Diseases, 2014, 209, 1921-1928.	1.9	77
51	Disease Progression in Plasmodium knowlesi Malaria Is Linked to Variation in Invasion Gene Family Members. PLoS Neglected Tropical Diseases, 2014, 8, e3086.	1.3	45
52	Pumped up: reflections on PfATP6 as the target for artemisinins. Trends in Pharmacological Sciences, 2014, 35, 4-11.	4.0	38
53	Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi. Malaria Journal, 2014, 13, 60.	0.8	59
54	Proteomic analysis of the Plasmodium male gamete reveals the key role for glycolysis in flagellar motility. Malaria Journal, 2014, 13, 315.	0.8	50

#	Article	IF	Citations
55	Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand. Malaria Journal, 2013, 12, 229.	0.8	27
56	Glutathione Transport: A New Role for PfCRT in Chloroquine Resistance. Antioxidants and Redox Signaling, 2013, 19, 683-695.	2.5	50
57	Studies with the Plasmodium falciparum hexokinase reveal that PfHT limits the rate of glucose entry into glycolysis. FEBS Letters, 2013, 587, 3182-3187.	1.3	19
58	Artemisinin resistance needs to be defined rigorously to be understood: response to Dondorp and Ringwald. Trends in Parasitology, 2013, 29, 361-362.	1.5	3
59	Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends in Parasitology, 2013, 29, 313-317.	1.5	61
60	Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malaria Journal, 2013, 12, 425.	0.8	44
61	New biomarkers for stage determination in Trypanosoma brucei rhodesiense sleeping sickness patients. Clinical and Translational Medicine, 2013, 2, 1.	1.7	52
62	Neopterin Is a Cerebrospinal Fluid Marker for Treatment Outcome Evaluation in Patients Affected by Trypanosoma brucei gambiense Sleeping Sickness. PLoS Neglected Tropical Diseases, 2013, 7, e2088.	1.3	25
63	The Plasmodium berghei Ca2+/H+ Exchanger, PbCAX, Is Essential for Tolerance to Environmental Ca2+ during Sexual Development. PLoS Pathogens, 2013, 9, e1003191.	2.1	35
64	Expression in Yeast Links Field Polymorphisms in PfATP6 to in Vitro Artemisinin Resistance and Identifies New Inhibitor Classes. Journal of Infectious Diseases, 2013, 208, 468-478.	1.9	25
65	African Trypanosomiasis. , 2013, , 718-724.		1
66	Adjunctive management of malaria. Current Opinion in Infectious Diseases, 2012, 25, 484-488.	1.3	13
67	A Simplified Intravenous Artesunate Regimen for Severe Malaria. Journal of Infectious Diseases, 2012, 205, 312-319.	1.9	38
68	Laboratory markers of disease severity in Plasmodium knowlesi infection: a case control study. Malaria Journal, 2012, 11, 363.	0.8	54
69	Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections. Malaria Journal, 2012, 11, 131.	0.8	30
70	Cytoadherence and virulence - the case of Plasmodium knowlesi malaria. Malaria Journal, 2012, 11, 33.	0.8	45
71	Cerebrospinal Fluid Neopterin as Marker of the Meningo-Encephalitic Stage of Trypanosoma brucei gambiense Sleeping Sickness. PLoS ONE, 2012, 7, e40909.	1.1	41
72	Rapid Diagnostic Algorithms as a Screening Tool for Tuberculosis: An Assessor Blinded Cross-Sectional Study. PLoS ONE, 2012, 7, e49658.	1.1	9

#	Article	IF	Citations
73	Non-Antifolate Antibiotics: Clindamycin, Doxycycline, Azithromycin and Fosmidomycin. , 2011, , 141-156.		1
74	Likely Health Outcomes for Untreated Acute Febrile Illness in the Tropics in Decision and Economic Models; A Delphi Survey. PLoS ONE, 2011, 6, e17439.	1.1	50
75	Anti-Inflammatory Cytokines Predominate in Acute Human Plasmodium knowlesi Infections. PLoS ONE, 2011, 6, e20541.	1.1	43
76	More depth of field not wider focus needed. Trends in Parasitology, 2011, 27, 3-4.	1.5	2
77	In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 2011, 67, 569-577.	1.1	46
78	Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa. Malaria Journal, 2011, 10, 165.	0.8	40
79	Artemisone Uptake in Plasmodium falciparum -Infected Erythrocytes. Antimicrobial Agents and Chemotherapy, 2011, 55, 550-556.	1.4	13
80	The Molecular Basis of Folate Salvage in Plasmodium falciparum. Journal of Biological Chemistry, 2011, 286, 44659-44668.	1.6	46
81	Use of a Selective Inhibitor To Define the Chemotherapeutic Potential of the Plasmodial Hexose Transporter in Different Stages of the Parasite's Life Cycle. Antimicrobial Agents and Chemotherapy, 2011, 55, 2824-2830.	1.4	39
82	Exploiting the therapeutic potential of Plasmodium falciparum solute transporters. Trends in Parasitology, 2010, 26, 284-296.	1.5	28
83	Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends in Parasitology, 2010, 26, 517-523.	1.5	54
84	Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality. Molecular Microbiology, 2010, 75, 1402-1413.	1.2	71
85	Investigations into the Role of the Plasmodium falciparum SERCA (PfATP6) L263E Mutation in Artemisinin Action and Resistance. Antimicrobial Agents and Chemotherapy, 2010, 54, 3842-3852.	1.4	52
86	Purified E255L Mutant SERCA1a and Purified PfATP6 Are Sensitive to SERCA-type Inhibitors but Insensitive to Artemisinins. Journal of Biological Chemistry, 2010, 285, 26406-26416.	1.6	58
87	Nitric oxide generation in children with malaria and the NOS2G-954C promoter polymorphism. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R1248-R1253.	0.9	15
88	Proteomic approaches in the search for biomarkers of liver fibrosis. Trends in Molecular Medicine, 2010, 16, 171-183.	3.5	20
89	Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report. Malaria Journal, 2010, 9, 10.	0.8	153
90	Prognostic Value of Circulating Pigmented Cells in African Children with Malaria. Journal of Infectious Diseases, 2009, 199, 142-150.	1.9	52

#	Article	IF	Citations
91	Comparison of effects of green tea catechins on apicomplexan hexose transporters and mammalian orthologues. Molecular and Biochemical Parasitology, 2009, 168, 113-116.	0.5	25
92	Blood volume and red cell mass in children with moderate and severe malaria measured by chromiumâ€53 dilution and gas chromatography/mass spectrometric analysis. Rapid Communications in Mass Spectrometry, 2009, 23, 2467-2475.	0.7	6
93	Plasmodium berghei-infection induces volume-regulated anion channel-like activity in human hepatoma cells. Cellular Microbiology, 2009, 11, 1492-1501.	1.1	12
94	Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet, The, 2009, 373, 557-566.	6.3	185
95	Effect of Artemisinins and Amino Alcohol Partner Antimalarials on Mammalian Sarcoendoplasmic Reticulum Calcium Adenosine Triphosphatase Activity. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 209-213.	1.2	17
96	Identification, expression and characterisation of a Babesia bovis hexose transporter. Molecular and Biochemical Parasitology, 2008, 161, 124-129.	0.5	13
97	New antimalarial targets: The example of glucose transport. Travel Medicine and Infectious Disease, 2008, 6, 58-66.	1.5	20
98	Artemisinins: their growing importance in medicine. Trends in Pharmacological Sciences, 2008, 29, 520-527.	4.0	301
99	Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infectious Diseases, The, 2008, 8, 777-784.	4.6	308
100	Estimation of Relevant Variables on High-Dimensional Biological Patterns Using Iterated Weighted Kernel Functions. PLoS ONE, 2008, 3, e1806.	1.1	7
101	Randomized, Controlled Trial of Treatments for Secondâ€Stage Sleeping Sickness. Journal of Infectious Diseases, 2007, 196, 650-651.	1.9	1
102	Mechanism of Antimalarial Action of the Synthetic Trioxolane RBX11160 (OZ277). Antimicrobial Agents and Chemotherapy, 2007, 51, 667-672.	1.4	68
103	Intrahost Selection of*Plasmodium falciparum* pfmdr1Alleles after Antimalarial Treatment on the Northwestern Border of Thailand. Journal of Infectious Diseases, 2007, 195, 134-141.	1.9	42
104	Artemisinins Inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense In Vitro Growth. Antimicrobial Agents and Chemotherapy, 2007, 51, 1852-1854.	1.4	116
105	The Fe²⁺â€Mediated Decomposition, PfATP6 Binding, and Antimalarial Activities of Artemisone and Other Artemisinins: The Unlikelihood of Câ€Centered Radicals as Bioactive Intermediates. ChemMedChem, 2007, 2, 1480-1497.	1.6	107
106	Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 655-659.	0.7	52
107	Interaction of O-(undec-10-en)-yl-d-glucose derivatives with the Plasmodium falciparum hexose transporter (PfHT). Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4934-4937.	1.0	17
108	Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nature Genetics, 2007, 39, 120-125.	9.4	184

#	Article	IF	Citations
109	The role of pfmdr1 in Plasmodium falciparum tolerance to artemetherâ€lumefantrine in Africa. Tropical Medicine and International Health, 2007, 12, 736-742.	1.0	127
110	Delayed parasite elimination in human infections treated with clindamycin parallels â€˜delayed deathâ€™ of Plasmodium falciparum in vitro. International Journal for Parasitology, 2007, 37, 777-785.	1.3	27
111	Geschichte und Zukunft der Medizinischen Forschung am Albert Schweitzer Spital in LambarÃ©nÃ©, Gabun. Wiener Klinische Wochenschrift, 2007, 119, 8-12.	1.0	52
112	Artesunate versus quinine for severe falciparum malaria. Lancet, The, 2006, 367, 110-111.	6.3	11
113	Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet, The, 2006, 368, 1012-1021.	6.3	240
114	Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends in Molecular Medicine, 2006, 12, 200-205.	3.5	82
115	Probing structure/affinity relationships for the Plasmodium falciparum hexose transporter with glucose derivatives. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1267-1271.	1.0	13
116	Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 615-622.	0.7	81
117	Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cellular and Molecular Life Sciences, 2006, 63, 1586-1596.	2.4	73
118	Ophthalmoplegia and Slurred Speech in an Intravenous Drug User. PLoS Medicine, 2006, 3, e453.	3.9	4
119	Population Pharmacokinetics of Artesunate and Dihydroartemisinin following Intra-Rectal Dosing of Artesunate in Malaria Patients. PLoS Medicine, 2006, 3, e444.	3.9	59
120	Drug Development Papers in PLoS Medicine: How We Try to Spot a Winner. PLoS Medicine, 2006, 3, e547.	3.9	2
121	Recurrent Gene Amplification and Soft Selective Sweeps during Evolution of Multidrug Resistance in Malaria Parasites. Molecular Biology and Evolution, 2006, 24, 562-573.	3.5	138
122	Decreasingpfmdr1Copy Number inPlasmodium falciparumMalaria Heightens Susceptibility to Mefloquine, Lumefantrine, Halofantrine, Quinine, and Artemisinin. Journal of Infectious Diseases, 2006, 194, 528-535.	1.9	326
123	Molecular and Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in Multidrug-Resistant Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2006, 42, 1570-1577.	2.9	258
124	Reply to Ursing et al.. Journal of Infectious Diseases, 2006, 194, 718-719.	1.9	2
125	Antimalarial Activity of a Synthetic Endoperoxide (RBx-11160/OZ277) against Plasmodium falciparum Isolates from Gabon. Antimicrobial Agents and Chemotherapy, 2006, 50, 1535-1537.	1.4	23
126	The relevance of malaria pathophysiology to strategies of clinical management. Current Opinion in Infectious Diseases, 2005, 18, 369-375.	1.3	27

#	Article	IF	Citations
127	The Nramp orthologue of Cryptococcus neoformans is a pH-dependent transporter of manganese, iron, cobalt and nickel. Biochemical Journal, 2005, 385, 225-232.	1.7	34
128	A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nature Structural and Molecular Biology, 2005, 12, 628-629.	3.6	232
129	Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends in Parasitology, 2005, 21, 154-157.	1.5	32
130	Trypanosomiasis: African and American. Medicine, 2005, 33, 50-53.	0.2	3
131	The Prognostic Value of Measures of Acid/Base Balance in Pediatric Falciparum Malaria, Compared with Other Clinical and Laboratory Parameters. Clinical Infectious Diseases, 2005, 41, 948-957.	2.9	45
132	Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment ofPlasmodium falciparum Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases, 2005, 40, 1777-1784.	2.9	64
133	Amplification ofPlasmodium falciparumMultidrug Resistance Gene 1 in Isolates from Gabon. Journal of Infectious Diseases, 2005, 192, 1830-1835.	1.9	56
134	Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet, The, 2005, 366, 486-487.	6.3	46
135	Artemisinins. Postgraduate Medical Journal, 2005, 81, 71-78.	0.9	200
136	Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malaria Journal, 2005, 4, 1.	0.8	155
137	Metal ion transport and regulation in mycobacterium tuberculosis. Frontiers in Bioscience - Landmark, 2004, 9, 2996.	3.0	56
138	Assessment of Volume Depletion in Children with Malaria. PLoS Medicine, 2004, 1, e18.	3.9	58
139	Retaking sleeping sickness control in Angola. Tropical Medicine and International Health, 2004, 9, 141-148.	1.0	36
140	Artemisinins: activities and actions. Microbes and Infection, 2004, 6, 1339-1346.	1.0	95
141	Aquaporinâ€4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB Journal, 2004, 18, 1291-1293.	0.2	679
142	Inhibition of hexose transport and abrogation of pH homeostasis in the intraerythrocytic malaria parasite by anO-3-hexose derivative. FEBS Letters, 2004, 570, 93-96.	1.3	38
143	Artemisinins: mechanisms of action and potential for resistance. Drug Resistance Updates, 2004, 7, 233-244.	6.5	180
144	The hexose transporter of Plasmodium falciparum is a worthy drug target. Acta Tropica, 2004, 89, 371-374.	0.9	20

#	Article	IF	Citations
145	A novel and accurate diagnostic test for human African trypanosomiasis. Lancet, The, 2004, 363, 1358-1363.	6.3	137
146	Antimalarial combinations. Lancet, The, 2004, 364, 285-294.	6.3	233
147	Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet, The, 2004, 364, 438-447.	6.3	707
148	Analysis of Plasmodium vivax hexose transporters and effects of a parasitocidal inhibitor. Biochemical Journal, 2004, 381, 905-909.	1.7	19
149	Waking up to sleeping sickness. Trends in Parasitology, 2003, 19, 195-197.	1.5	63
150	Artemisinins target the SERCA of Plasmodium falciparum. Nature, 2003, 424, 957-961.	13.7	904
151	Case reports: pernicious complications of benign tertian malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 551-553.	0.7	32
152	Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7476-7479.	3.3	133
153	The trypanosomiases. Lancet, The, 2003, 362, 1469-1480.	6.3	673
154	A Prospective Comparison of Malaria with Other Severe Diseases in African Children: Prognosis and Optimization of Management. Clinical Infectious Diseases, 2003, 37, 890-897.	2.9	48
155	Short-Course Artesunate Treatment of Uncomplicated Plasmodium falciparum Malaria in Gabon. Antimicrobial Agents and Chemotherapy, 2003, 47, 901-904.	1.4	35
156	Multiple Splice Variants Encode a Novel Adenylyl Cyclase of Possible Plastid Origin Expressed in the Sexual Stage of the Malaria Parasite Plasmodium falciparum. Journal of Biological Chemistry, 2003, 278, 22014-22022.	1.6	61
157	Antiprotozoal drugs. Side Effects of Drugs Annual, 2003, 26, 315-327.	0.6	0
158	Population Kinetics, Efficacy, and Safety of Dichloroacetate for Lactic Acidosis Due to Severe Malaria in Children. Journal of Clinical Pharmacology, 2003, 43, 386-396.	1.0	49
159	Mutational Analysis of the Hexose Transporter of Plasmodium falciparum and Development of a Three-dimensional Model. Journal of Biological Chemistry, 2002, 277, 30942-30949.	1.6	12
160	Intramuscular Bioavailability and Clinical Efficacy of Artesunate in Gabonese Children with Severe Malaria. Antimicrobial Agents and Chemotherapy, 2002, 46, 3933-3939.	1.4	68
161	Antiprotozoal drugs. Side Effects of Drugs Annual, 2002, 25, 343-352.	0.6	0
162	Comparative characterization of hexose transporters of Plasmodium knowlesi, Plasmodium yoelii and Toxoplasma gondii highlights functional differences within the apicomplexan family. Biochemical Journal, 2002, 368, 923-929.	1.7	37

#	Article	IF	Citations
163	Human African trypanosomiasis. BMJ: British Medical Journal, 2002, 325, 203-206.	2.4	111
164	Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet, The, 2002, 359, 1365-1372.	6.3	259
165	Antimalarial cocktailâ€"tropical flavours of the month. Lancet, The, 2002, 360, 1998-1999.	6.3	10
166	Transport processes in Plasmodium falciparum-infected erythrocytes: potential as new drug targets. International Journal for Parasitology, 2002, 32, 1567-1573.	1.3	25
167	Increased aquaporin 1 water channel expression inhuman brain tumours. British Journal of Cancer, 2002, 87, 621-623.	2.9	254
168	Antiprotozoal drugs. Side Effects of Drugs Annual, 2001, , 330-339.	0.6	0
169	Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathology and Applied Neurobiology, 2001, 27, 384-395.	1.8	113
170	Characterization of P-type ATPase 3 in Plasmodium falciparum. Molecular and Biochemical Parasitology, 2001, 116, 117-126.	0.5	13
171	Transport proteins of Plasmodium falciparum: defining the limits of metabolism. International Journal for Parasitology, 2001, 31, 1331-1342.	1.3	21
172	Population Pharmacokinetics of Intramuscular Quinine in Children with Severe Malaria. Antimicrobial Agents and Chemotherapy, 2001, 45, 1803-1809.	1.4	48
173	Bioavailability and Preliminary Clinical Efficacy of Intrarectal Artesunate in Ghanaian Children with Moderate Malaria. Antimicrobial Agents and Chemotherapy, 2001, 45, 509-516.	1.4	93
174	Expression and Functional Characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) Belonging to a Subclass Unique to Apicomplexan Organisms. Journal of Biological Chemistry, 2001, 276, 10782-10787.	1.6	89
175	Rainbow trout glucose transporter (OnmyGLUT1): functional assessment inXenopus laevisoocytes and expression in fish embryos. Journal of Experimental Biology, 2001, 204, 2667-2673.	0.8	24
176	Antiprotozoal drugs. Side Effects of Drugs Annual, 2000, , 304-313.	0.6	0
177	Glucose and Lactate Kinetics in Children with Severe Malaria¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1569-1576.	1.8	61
178	The Trypanosoma cruzi genome contains ion motive ATPase genes which closely resemble Leishmania proton pumps. Parasitology International, 2000, 49, 309-320.	0.6	9
179	Glucose and Lactate Kinetics in Children with Severe Malaria. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1569-1576.	1.8	54
180	Mycobacterium tuberculosis Expresses a Novel Ph-Dependent Divalent Cation Transporter Belonging to the Nramp Family. Journal of Experimental Medicine, 1999, 190, 717-724.	4.2	131

#	Article	IF	Citations
181	Recent developments in the management of malaria. Indian Journal of Pediatrics, 1999, 66, 103-109.	0.3	2
182	Gametocyte-dominant expression of a novel P-type ATPase in Plasmodium yoelii. Molecular and Biochemical Parasitology, 1999, 104, 331-336.	0.5	9
183	Antiprotozoal drugs. Side Effects of Drugs Annual, 1999, , 302-316.	0.6	0
184	Thiamine deficiency and malaria in adults from southeast Asia. Lancet, The, 1999, 353, 546-549.	6.3	71
185	Intraerythrocytic Plasmodium falciparum Expresses a High Affinity Facilitative Hexose Transporter. Journal of Biological Chemistry, 1999, 274, 7272-7277.	1.6	129
186	Expression of Parasite Transporters in Xenopus Oocytes. Novartis Foundation Symposium, 1999, 226, 126-144.	1.2	2
187	Crithidia luciliae: Functional Expression of Nucleoside and Nucleobase Transporters inXenopus laevisOocytes. Experimental Parasitology, 1998, 90, 181-188.	0.5	5
188	Expression of substrate-specific transporters encoded by Plasmodium falciparum in Xenopus laevis oocytes. Molecular and Biochemical Parasitology, 1998, 93, 81-89.	0.5	30
189	Metal ion homeostasis and intracellular parasitism. Molecular Microbiology, 1998, 28, 403-412.	1.2	100
190	Severe Falciparum Malaria in Children Current Understanding of Pathophysiology and Supportive Treatment. , 1998, 79, 1-53.		307
191	Antiprotozoal drugs. Side Effects of Drugs Annual, 1998, , 293-305.	0.6	0
192	Polymerase chain reaction for the detection of Burkholderia pseudomallei. Diagnostic Microbiology and Infectious Disease, 1997, 29, 121-127.	0.8	21
193	P-Type ATPases in Tetrahymena. Annals of the New York Academy of Sciences, 1997, 834, 158-160.	1.8	4
194	Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction. Molecular and Biochemical Parasitology, 1997, 85, 161-169.	0.5	31
195	Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 298-302.	0.7	34
196	Science, medicine, and the future : malaria. BMJ: British Medical Journal, 1997, 315, 730-732.	2.4	13
197	Pharmacokinetics of Quinine, Chloroquine and Amodiaquine. Clinical Pharmacokinetics, 1996, 30, 263-299.	1.6	257
198	The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. British Journal of Clinical Pharmacology, 1996, 41, 29-34.	1.1	21

#	Article	IF	Citations
199	Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 67-73.	0.7	231
200	Plasmodium falciparum: In Vitro Studies of the Pharmacodynamic Properties of Drugs Used for the Treatment of Severe Malaria. Experimental Parasitology, 1993, 76, 85-95.	0.5	250
201	Expression of thrombospondin-related anonymous protein in Plasmodium falciparum sporozoites. Lancet, The, 1992, 339, 1412-1413.	6.3	49
202	Tandem competitive polymerase chain reaction (TC-PCR): a method for determining ratios of RNA and DNA templates. Molecular and Cellular Probes, 1992, 6, 375-380.	0.9	9
203	Erythrocyte survival in severe falciparum malaria. Acta Tropica, 1991, 48, 263-270.	0.9	77
204	Plasmodium berghei: Lactic acidosis and hypoglycaemia in a rodent model of severe malaria; effects of glucose, quinine, and dichloroacetate. Experimental Parasitology, 1991, 72, 123-133.	0.5	25
205	The pituitary-thyroid axis in severe falciparum malaria: evidence for depressed thyrotroph and thyroid gland function. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 330-335.	0.7	18
206	Telomere-related sequences at interstitial sites in the human genome. Genomics, 1990, 8, 699-704.	1.3	72
207	Management of severe malarial infection. Indian Journal of Pediatrics, 1989, 56, 155-163.	0.3	2
208	Cation metabolism in malaria-infected red cells. Experimental Parasitology, 1989, 69, 402-406.	0.5	20
209	Severe Hypoglycemia and Hyperinsulinemia in Falciparum Malaria. New England Journal of Medicine, 1983, 309, 61-66.	13.9	416
210	Molecular Approaches to Malaria: Glycolysis in Asexual-Stage Parasites. , 0, , 221-233.		1
211	Plasmodium knowlesi: the Fifth Human Malarial Parasite. , 0, , 261-271.		0